The evolution of drug-resistant malaria: The role of drug elimination half-life

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 357, Issue 1420, 2002, Pages 505-519

  Hastings, Ian M ^a   Watkins, William M ^a   White, Nicholas J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibiotics; Drug half life; Drug resistance; Malaria; Plasmodium falciparum

Indexed keywords

DRUG RESISTANCE; EVOLUTION; MALARIA;

BACTERIA (MICROORGANISMS); PLASMODIUM FALCIPARUM;

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; DIHYDROFOLATE REDUCTASE;

ANIMAL; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; EVOLUTION; GENETICS; HALF LIFE TIME; HUMAN; MALARIA; PARASITOLOGY; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; DRUG COMBINATIONS; DRUG RESISTANCE; EVOLUTION; HALF-LIFE; HUMANS; MALARIA; PLASMODIUM FALCIPARUM; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0037192926     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2001.1036     Document Type: Article

References (40)

1. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission
2. The dynamics of drug action on the within-host population growth of infectious agents: Melding pharmacokinetics with pathogen population dynamics
3. Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs
4. A simple model of the build-up of resistance to mixtures of anti-malarial drugs
5. Multigenic drug resistance among inbred malaria parasites
6. Cost-effectiveness of malaria control in sub-Saharan Africa
7. A model for the origins and spread of drug resistant malaria
8. Modelling a predictable disaster: The rise and spread of drug-resistant malaria
9. Interindividual variation in the metabolic-activation of the antimalarial biguanides
10. Costs and benefits of resistance against antimalarial drugs
11. The population biology of anti-infective chemotherapy and the evolution of drug resistance: More questions than answers
12. The population dynamics of antimicrobial chemotherapy
13. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates: From Kilifi, Kenya
14. Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. 4. Effects on incidence of malaria infection
15. Kenyan Plasmodium falciparum field isolates: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain
16. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites
17. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine-sulfadoxine compared with the shorter acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum
18. Chemotherapy and drug resistance in malaria
19. The prevention of antimalarial drug-resistance
20. Economic implications of resistance to antimalarial drugs
21. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance
22. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria
23. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum attacks treated with chloroquine or sulfadoxine plus pyrimethamine
24. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population
25. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: Use of simultaneous measurement by high performance liquid chromatography and bioassay
26. Impact of chloroquine resistance on malaria mortality
27. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone
28. Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
29. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man
30. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long half-life
31. A preliminary pharmacokinetic study of the antimalarial-drugs, proguanil and chlorproguanil
32. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults
33. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
34. Preventing antimalarial drug resistance through combinations
35. Antimalaria drug resistance and combination chemotherapy
36. Strategies for the prevention of antimalarial drug resistance rationale for combination chemotherapy for malaria
37. Averting a malaria disaster
38. Chemotherapy for falciparum malaria: The armoury, the problems, and the prospects